Market Closed -
Other stock markets
|
Pre-market 04:35:00 pm | |||
1.09 USD | -3.54% | 1.115 | +2.29% |
Valuation
Fiscal Period: October | 2021 | 2022 | 2023 |
---|---|---|---|
Capitalization 1 | 22.25 | 10.43 | 1.784 |
Enterprise Value (EV) 2 | 17.65 | 10.04 | -3.73 |
P/E ratio | -4.23 x | -1.09 x | -0.09 x |
Yield | - | - | - |
Capitalization / Revenue | - | - | - |
EV / Revenue | - | - | - |
EV / EBITDA | -48,04,206 x | -11,80,698 x | 5,93,760 x |
EV / FCF | -11.1 x | -8.4 x | 6.13 x |
FCF Yield | -8.97% | -11.9% | 16.3% |
Price to Book | 4.63 x | -6.91 x | 2.26 x |
Nbr of stocks (in thousands) | 41.7 | 44 | 488 |
Reference price 3 | 533.6 | 237.0 | 3.657 |
Announcement Date | 28/02/22 | 31/01/23 | 29/01/24 |
Income Statement Evolution (Annual data)
Fiscal Period: October | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA | - | - | - | -3.674 | -8.502 | -6.281 |
EBIT 1 | -0.2174 | -0.086 | -0.2086 | -3.866 | -8.533 | -6.303 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -0.1945 | -0.1053 | -0.2332 | -3.899 | -9.37 | -8.603 |
Net income 1 | -0.1945 | -0.1053 | -0.2332 | -3.899 | -9.411 | -8.621 |
Net margin | - | - | - | - | - | - |
EPS 2 | -18.05 | -8.537 | -12.86 | -126.2 | -217.2 | -42.58 |
Free Cash Flow 1 | -0.1781 | -0.0215 | -0.1716 | -1.583 | -1.195 | -0.6085 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 25/02/19 | 28/02/20 | 01/03/21 | 28/02/22 | 31/01/23 | 29/01/24 |
Balance Sheet Analysis
Fiscal Period: October | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 0.07 | 0 | 0.33 | 4.6 | 0.39 | 5.51 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -0.18 | -0.02 | -0.17 | -1.58 | -1.2 | -0.61 |
ROE (net income / shareholders' equity) | -129% | -56.5% | -73.7% | -147% | -572% | 14,072% |
ROA (Net income/ Total Assets) | -72.3% | -25.3% | -37.7% | -85.2% | -170% | -116% |
Assets 1 | 0.269 | 0.4163 | 0.6181 | 4.577 | 5.547 | 7.418 |
Book Value Per Share 2 | 19.40 | 10.80 | 23.40 | 115.0 | -34.30 | 1.620 |
Cash Flow per Share 2 | 5.980 | 0.0600 | 15.40 | 110.0 | 4.000 | 8.940 |
Capex 1 | 0.13 | 0.01 | 0.01 | 0.03 | 0.01 | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 25/02/19 | 28/02/20 | 01/03/21 | 28/02/22 | 31/01/23 | 29/01/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-61.21% | 3.56M | |
+48.64% | 56.65B | |
-6.44% | 39.44B | |
+39.04% | 39.03B | |
+14.28% | 26.75B | |
-11.17% | 26.86B | |
-21.40% | 19.03B | |
+25.64% | 12.26B | |
+0.96% | 12.28B | |
+27.04% | 12.04B |
- Stock Market
- Equities
- CMND Stock
- Financials Clearmind Medicine Inc.